Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.98

+1.1%

Nov 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who started this subject	6/21/2004 2:19:11 PM
From: tom pope	Read Replies (1) of 52153

Any Platinum members out there? (no rude jokes in reply, please) Based on the number of biotech deals coming to market this year, one would surmise that the group is experiencing strong demand. A few deals have done well, but the vast majority have floundered. Biotech offerings continue to face downwardly revised price ranges; and, despite a number of these deals breaking their offering prices, underwriters continue to bring biotechs public. However, where there is misery, investors/traders often find opportunity. On our Small Cap Focus page, we look at some of the biotech deals that have come to market this year. The goal is to provide a hit list of broken deals for traders to refer to should the biotech market heat up later this year. Platinum members can click here for the report.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next